Aimmune Therapeutics (NASDAQ:AIMT) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday, October 17th.
A number of other brokerages also recently commented on AIMT. BidaskClub downgraded Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 19th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 24th. Stifel Nicolaus began coverage on Aimmune Therapeutics in a research report on Thursday, September 13th. They set a “hold” rating and a $33.00 price objective for the company. Wedbush began coverage on Aimmune Therapeutics in a research report on Wednesday, October 17th. They set a “buy” rating and a $72.00 price objective for the company. Finally, Credit Suisse Group set a $40.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a report on Monday, August 13th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $50.70.
AIMT traded up $2.04 during trading on Wednesday, reaching $30.29. The stock had a trading volume of 607,251 shares, compared to its average volume of 510,847. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -11.61 and a beta of -0.10. Aimmune Therapeutics has a 1-year low of $24.56 and a 1-year high of $42.00.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.03. As a group, research analysts predict that Aimmune Therapeutics will post -3.64 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Tiverton Asset Management LLC acquired a new position in shares of Aimmune Therapeutics in the second quarter worth $145,000. Ardsley Advisory Partners acquired a new position in shares of Aimmune Therapeutics in the second quarter worth $202,000. Xact Kapitalforvaltning AB acquired a new position in shares of Aimmune Therapeutics in the first quarter worth $207,000. Atria Investments LLC acquired a new position in shares of Aimmune Therapeutics in the third quarter worth $213,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Aimmune Therapeutics in the first quarter worth $262,000. 78.16% of the stock is currently owned by institutional investors and hedge funds.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Featured Story: Understanding Market Liquidity
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.